{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:57:50Z","timestamp":1791291470892,"version":"4.3.0"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T00:00:00Z","timestamp":1240963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>We have recently shown a significant reduction in cytokine\u2010induced transcription of type I collagen and fibronectin in systemic sclerosis (SSc) skin fibroblasts upon treatment with trichostatin A (TSA). Moreover, in a mouse model of fibrosis, TSA prevented the dermal accumulation of extracellular matrix. The purpose of this study was to analyze the silencing of histone deacetylase 7 (HDAC\u20107) as a possible mechanism by which TSA exerts its antifibrotic function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Skin fibroblasts from patients with SSc were treated with TSA and\/or transforming growth factor \u03b2. Expression of HDACs 1\u201311, extracellular matrix proteins, connective tissue growth factor (CTGF), and intercellular adhesion molecule 1 (ICAM\u20101) was analyzed by real\u2010time polymerase chain reaction, Western blotting, and the Sircol collagen assay. HDAC\u20107 was silenced using small interfering RNA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>SSc fibroblasts did not show a specific pattern of expression of HDACs. TSA significantly inhibited the expression of HDAC\u20107, whereas HDAC\u20103 was up\u2010regulated. Silencing of HDAC\u20107 decreased the constitutive and cytokine\u2010induced production of type I and type III collagen, but not fibronectin, as TSA had done. Most interestingly, TSA induced the expression of CTGF and ICAM\u20101, while silencing of HDAC\u20107 had no effect on their expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Silencing of HDAC\u20107 appears to be not only as effective as TSA, but also a more specific target for the treatment of SSc, because it does not up\u2010regulate the expression of profibrotic molecules such as ICAM\u20101 and CTGF. This observation may lead to the development of more specific and less toxic targeted therapies for SSc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.24494","type":"journal-article","created":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T10:52:59Z","timestamp":1241002379000},"page":"1519-1529","source":"Crossref","is-referenced-by-count":101,"title":["Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis"],"prefix":"10.1002","volume":"60","author":[{"given":"Hossein","family":"Hemmatazad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna Maciejewska","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabia","family":"Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Pileckyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg H. W.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate E.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat A.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars C.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"J\u00fcngel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,29]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.45.120403.095825"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(03)00235-1"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21948"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.21162"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.12.204"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22759"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3747\/co.v15i5.371","article-title":"Histone deacetylase inhibitors as novel anticancer therapeutics","volume":"15","author":"Walkinshaw DR","year":"2008","journal-title":"Curr Oncol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.20781"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1677\/jme.1.02138"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20532"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)44885-X"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20070779"},{"key":"e_1_2_6_14_2","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy EC","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22980"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68737-0"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken265"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.107.149377"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2007.05.014"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.1.698"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867043365099"},{"key":"e_1_2_6_22_2","first-page":"245","article-title":"The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation","volume":"5","author":"Van Lint C","year":"1996","journal-title":"Gene Expr"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0500369102"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/10408440590935639"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.12.1320"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.07.080"},{"key":"e_1_2_6_27_2","first-page":"971","article-title":"Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo","volume":"7","author":"Vigushin DM","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_28_2","first-page":"4916","article-title":"FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases","volume":"62","author":"Furumai R","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0430973100"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.8.2873-2884.2005"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07438.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200111000-00010"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.2302\/kjm.53.74"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0251"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.02091-06"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00109-2"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101508200"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-07-0324"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.05.040"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M406320200"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.14.1.55"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M104935200"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.24494","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.24494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T22:55:54Z","timestamp":1697064954000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.24494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,29]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1002\/art.24494"],"URL":"https:\/\/doi.org\/10.1002\/art.24494","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,29]]}}}